Shopify's Q3 Earnings Decline, Revenue Increases; Shares Fall Premarket-February 2024-www.financetom.com

Shopify's Q3 Earnings Decline, Revenue Increases; Shares Fall Premarket

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Shopify's Q3 Earnings Decline, Revenue Increases; Shares Fall Premarket

Nov 4, 2025 5:07 AM

07:32 AM EST, 11/04/2025 (MT Newswires) -- Shopify ( SHOP ) reported Q3 earnings Tuesday of $0.20 per diluted share, down from $0.64 a year earlier.

Analysts polled by FactSet expected $0.26.

Revenue for the quarter ended Sept. 30 was $2.84 billion, compared with $2.16 billion a year earlier.

Analysts polled by FactSet expected $2.76 billion.

The company said it expects Q4 revenue growth at a mid-to-high-twenties percentage rate.

Shares of Shopify ( SHOP ) were down 3% in recent premarket activity.

Previous page： Aalberts N.V.: Aalberts completes acquisition of Grand Venture Technology Limited Next page： Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Aalberts N.V.: Aalberts completes acquisition of Grand Venture Technology Limited

Oct 30, 2025

Utrecht, 31 October 2025 Aalberts ( AALBF ) completes acquisition of Grand Venture Technology Limited Aalberts ( AALBF ) announces successful completion of the acquisition of Grand Venture Technology Limited (GVT). With its head office in Singapore, GVT operates six facilities across Singapore, Malaysia and China, generating an annual revenue of SGD 160 million in 2024 and an adjusted EBITDA...

Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know

Oct 30, 2025

Intensity Therapeutics Inc. ( INTS ) shares are trending on Friday. Check out the current price of INTS stock here. Shares of the biotechnology company rallied 394.9% in Thursday's regular session after Phase 1/2 clinical trial results for INT230‑6, an intratumoral therapy combining cisplatin and vinblastine sulfate, were published in eBioMedicine, but the gains tapered in after-hours trading to $0.90,...

Form 8.3 - Offeree = Big Yellow Group plc

Oct 31, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Long Pond Capital, LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...

Corbus Pharmaceuticals Announces Pricing of Public Offering

Oct 30, 2025

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP ) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants...